Grade >= neuropathy Note: Subjects with ? Grade neuropathy or ? Grade alopecia are an exception to this criterion and may qualify for the study. >= grade neuropathy at the time of enrollment Neuropathy > grade Significant neuropathy (Grade , Grade , or Grade with pain) at the time of the first dose and/or within days before enrollment Neuropathy ? Grade . Patients with a history of grade >= neuropathy Patients with >= grade neuropathy Significant neuropathy > grade at the time of first dose or within days of enrollment Neuropathy > grade Patients with grade or greater neuropathy Grade or above neuropathy induced from prior treatment, that is not resolved to grade or below despite best supportive care Grade or greater neuropathy Patients who have residual toxicities > grade attributed to taxane therapy, except for neuropathy, who are excluded if > grade Neuropathy: patients must have =< grade neuropathy at enrollment Neuropathy =< grade at the time of registration Neuropathy grade > Grade or greater neuropathy Neuropathy >= grade Have grade or greater neuropathy at the time of screening Uncontrolled neuropathy grade or greater, regardless of cause No prior evidence of grade or greater ototoxicity or neuropathy Significant neuropathy (grade , grade ) at the time of the first dose and/or within days before enrollment Neuropathy > Grade Patients with >= grade neuropathy No grade >= neuropathy Ongoing grade >= neuropathy Subjects with grade or greater neuropathy Grade or greater neuropathy Neuropathy Grade > Grade or greater neuropathy [Applies to Phase ]. Grade or greater neuropathy [Applies to Phase ]. Grade <= neuropathy Patients with > grade neuropathy Subjects with >= grade neuropathy Evidence of ? Grade neuropathy Neuropathy > Grade . Patients with >= grade neuropathy Grade or greater neuropathy Uncontrolled neuropathy grade or greater regardless of cause. Significant neuropathy (? Grade ) within the days prior to randomization Subjects with >= grade neuropathy Significant neuropathy (Grade , Grade , or Grade with pain) at the time of first dose > Grade neuropathy Significant neuropathy (Grade , Grade , or Grade with pain) at the time of the first dose Peripheral neuropathy Grade , Grade or Grade with pain within days prior to randomization. Grade > neuropathy History of Grade ? neuropathy Neuropathy > grade ? Grade- neuropathy Greater than or equal to Grade- neuropathy No current grade , , or of neuropathy Patients with any neuropathy > Grade Patients with grade > neuropathy attributable to previous administration of taxane chemotherapy Severe neuropathy greater than or equal to grade Patients with neuropathy > grade Subject has Neuropathy ? Grade at Screening. With < or = grade neuropathy > grade neuropathy Patients with grade III-IV neuropathy Grade or above neuropathy Presence of ? Grade neuropathy. Neuropathy Grade or more Significant peripheral neuropathy (Grade , Grade , or Grade with pain) within days prior to first dose Significant neuropathy (Grade , Grade , or Grade with pain) at the time of the first dose and/or within days before study treatment Grade >= neuropathy Grade disease Has neuropathy ? Grade .